MCL coexpression mm9:848
From FANTOM5_SSTAR
Phase1 CAGE Peaks
Short description | |
---|---|
Mm9::chr5:107788562..107788605,+ | p2@Brdt |
Mm9::chr9:43851294..43851336,+ | p2@Thy1 |
Mm9::chr9:43851473..43851517,+ | p1@Thy1 |
Mm9::chr9:43854810..43854849,- | p@chr9:43854810..43854849 - |
Mm9::chr9:43854871..43854901,+ | p@chr9:43854871..43854901 + |
Mm9::chr9:43854935..43854978,- | p@chr9:43854935..43854978 - |
Mm9::chr9:43854987..43854999,+ | p@chr9:43854987..43854999 + |
Mm9::chr9:43855655..43855666,+ | p@chr9:43855655..43855666 + |
Mm9::chr9:43856002..43856018,+ | p@chr9:43856002..43856018 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0042670 | retinal cone cell differentiation | 0.00597162110338027 |
GO:0046549 | retinal cone cell development | 0.00597162110338027 |
GO:0060042 | retina morphogenesis in camera-type eye | 0.00716555271254392 |
GO:0031362 | anchored to external side of plasma membrane | 0.00716555271254392 |
GO:0031233 | intrinsic to external side of plasma membrane | 0.00716555271254392 |
GO:0050858 | negative regulation of antigen receptor-mediated signaling pathway | 0.00852995250122804 |
GO:0050860 | negative regulation of T cell receptor signaling pathway | 0.00852995250122804 |
GO:0042393 | histone binding | 0.010103051914287 |
GO:0060041 | retina development in camera-type eye | 0.010103051914287 |
GO:0050856 | regulation of T cell receptor signaling pathway | 0.010103051914287 |
GO:0031225 | anchored to membrane | 0.010103051914287 |
GO:0046658 | anchored to plasma membrane | 0.010103051914287 |
GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 0.010103051914287 |
GO:0042462 | eye photoreceptor cell development | 0.0119376802103351 |
GO:0001754 | eye photoreceptor cell differentiation | 0.0119376802103351 |
GO:0042461 | photoreceptor cell development | 0.0119376802103351 |
GO:0048593 | camera-type eye morphogenesis | 0.0119376802103351 |
GO:0050852 | T cell receptor signaling pathway | 0.0119376802103351 |
GO:0046530 | photoreceptor cell differentiation | 0.0131931932796124 |
GO:0050851 | antigen receptor-mediated signaling pathway | 0.0161118930923894 |
GO:0002429 | immune response-activating cell surface receptor signaling pathway | 0.0181353277613955 |
GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 0.0181353277613955 |
GO:0002757 | immune response-activating signal transduction | 0.0181353277613955 |
GO:0006338 | chromatin remodeling | 0.0181353277613955 |
GO:0002764 | immune response-regulating signal transduction | 0.0181353277613955 |
GO:0048592 | eye morphogenesis | 0.0197295590217139 |
GO:0043010 | camera-type eye development | 0.0327755362301843 |
GO:0002253 | activation of immune response | 0.0327755362301843 |
GO:0050778 | positive regulation of immune response | 0.0389109199577307 |
GO:0002684 | positive regulation of immune system process | 0.0389109199577307 |
GO:0001654 | eye development | 0.0399545960452431 |
GO:0050776 | regulation of immune response | 0.0401367309985071 |
GO:0002682 | regulation of immune system process | 0.0401367309985071 |
GO:0051240 | positive regulation of multicellular organismal process | 0.0401367309985071 |
GO:0048503 | GPI anchor binding | 0.0401367309985071 |
GO:0001525 | angiogenesis | 0.0437371347021604 |
GO:0009897 | external side of plasma membrane | 0.0437371347021604 |
GO:0016043 | cellular component organization and biogenesis | 0.0460427918832516 |
GO:0035091 | phosphoinositide binding | 0.04904453936278 |
GO:0016568 | chromatin modification | 0.04904453936278 |
GO:0048514 | blood vessel morphogenesis | 0.0491152203408847 |
GO:0009986 | cell surface | 0.0491152203408847 |
GO:0000904 | cellular morphogenesis during differentiation | 0.0491152203408847 |
GO:0048646 | anatomical structure formation | 0.0491152203408847 |
GO:0007423 | sensory organ development | 0.0491152203408847 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |